Antonio Romano, Linda Balestrini, Giulia Della Scala, Lucia Chico, Alessio Bertini, Matilde Cangioli, Federico Ciapparelli, Enzo Ciardella, Claudia Congestrí, Valentina Dinelli, Fabio Donati, Massimo Ficini, Cecilia Giovanetti, Federico Nannicini, Alessandro Pasquali, Andrea Pieraccini
{"title":"肠易激综合征患者服用含有益生菌、Hericium、PEA 和 Undaria 的复合营养素的效果。","authors":"Antonio Romano, Linda Balestrini, Giulia Della Scala, Lucia Chico, Alessio Bertini, Matilde Cangioli, Federico Ciapparelli, Enzo Ciardella, Claudia Congestrí, Valentina Dinelli, Fabio Donati, Massimo Ficini, Cecilia Giovanetti, Federico Nannicini, Alessandro Pasquali, Andrea Pieraccini","doi":"10.1080/19390211.2023.2296106","DOIUrl":null,"url":null,"abstract":"<p><p>Irritable bowel syndrome (IBS) is a functional gastrointestinal condition. Probiotics and other nutraceutical compounds can have specific indications in the context of IBS. A retrospective analysis was conducted on 123 IBS patients in order to evaluate the effects of an oral probiotic-based dietary supplement (Colicron, one cps/day for 4 wk) on stool consistency and pain intensity. Different time points were defined as follows: baseline (T0), 2 wk of treatment (T2), and 4 wk of treatment (T4). Stool consistency was assessed by using the Bristol Stool Scale. Pain intensity was evaluated by the Visual Analogue Scale (VAS). Patients who were initially categorized as normal retained regular bowel movements throughout the study. Both patients with constipation and diarrhea showed an improvement in the Bristol Stool Scale. The score increased from 1.5 ± 0.5 to 3.3 ± 0.7 (<i>p</i> < 0.001) and decreased from 6.5 ± 0.7 to 4.3 ± 0.9 (<i>p</i> < 0.001) at T4, respectively, compared to T0. The VAS score for pain in the pooled IBS patients improved from 6.7 ± 2.2 to 2.8 ± 1.9 at T0 <i>vs</i> T4 (<i>p</i> < 0.001), with a similar trend also observed when patients were categorized based on stool consistency: normal (from 5.2 ± 1.9 to 2.9 ± 1.7), constipation (from 7.5 ± 1.3 to 3.2 ± 2.2), and diarrhea (6.7 ± 2.3 to 2.5 ± 1.9) (<i>p</i> < 0.001).</p><p><p>Colicron could be useful in symptom relief, reducing abdominal pain and improving stool consistency of IBS patients. However, further controlled clinical trials are needed to confirm these preliminary findings.</p>","PeriodicalId":15646,"journal":{"name":"Journal of Dietary Supplements","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effects of a Nutraceutical Multicompound, with Probiotics, Hericium, PEA, and Undaria in Patients with Irritable Bowel Syndrome.\",\"authors\":\"Antonio Romano, Linda Balestrini, Giulia Della Scala, Lucia Chico, Alessio Bertini, Matilde Cangioli, Federico Ciapparelli, Enzo Ciardella, Claudia Congestrí, Valentina Dinelli, Fabio Donati, Massimo Ficini, Cecilia Giovanetti, Federico Nannicini, Alessandro Pasquali, Andrea Pieraccini\",\"doi\":\"10.1080/19390211.2023.2296106\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Irritable bowel syndrome (IBS) is a functional gastrointestinal condition. Probiotics and other nutraceutical compounds can have specific indications in the context of IBS. A retrospective analysis was conducted on 123 IBS patients in order to evaluate the effects of an oral probiotic-based dietary supplement (Colicron, one cps/day for 4 wk) on stool consistency and pain intensity. Different time points were defined as follows: baseline (T0), 2 wk of treatment (T2), and 4 wk of treatment (T4). Stool consistency was assessed by using the Bristol Stool Scale. Pain intensity was evaluated by the Visual Analogue Scale (VAS). Patients who were initially categorized as normal retained regular bowel movements throughout the study. Both patients with constipation and diarrhea showed an improvement in the Bristol Stool Scale. The score increased from 1.5 ± 0.5 to 3.3 ± 0.7 (<i>p</i> < 0.001) and decreased from 6.5 ± 0.7 to 4.3 ± 0.9 (<i>p</i> < 0.001) at T4, respectively, compared to T0. The VAS score for pain in the pooled IBS patients improved from 6.7 ± 2.2 to 2.8 ± 1.9 at T0 <i>vs</i> T4 (<i>p</i> < 0.001), with a similar trend also observed when patients were categorized based on stool consistency: normal (from 5.2 ± 1.9 to 2.9 ± 1.7), constipation (from 7.5 ± 1.3 to 3.2 ± 2.2), and diarrhea (6.7 ± 2.3 to 2.5 ± 1.9) (<i>p</i> < 0.001).</p><p><p>Colicron could be useful in symptom relief, reducing abdominal pain and improving stool consistency of IBS patients. However, further controlled clinical trials are needed to confirm these preliminary findings.</p>\",\"PeriodicalId\":15646,\"journal\":{\"name\":\"Journal of Dietary Supplements\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Dietary Supplements\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/19390211.2023.2296106\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/8 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"NUTRITION & DIETETICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Dietary Supplements","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/19390211.2023.2296106","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0
摘要
肠易激综合征(IBS)是一种功能性胃肠道疾病。益生菌和其他营养保健品对肠易激综合征有特殊的适应症。我们对 123 名 IBS 患者进行了回顾性分析,以评估口服益生菌膳食补充剂(Colicron,1 cps/天,4 周)对大便稠度和疼痛强度的影响。不同的时间点定义如下:基线(T0)、治疗 2 周(T2)和治疗 4 周(T4)。大便稠度采用布里斯托尔大便量表进行评估。疼痛强度采用视觉模拟量表(VAS)进行评估。最初被归类为正常的患者在整个研究过程中都保持了规律的排便。便秘和腹泻患者的布里斯托大便量表均有改善。分值从 1.5 ± 0.5 增加到 3.3 ± 0.7(p p vs T4(p p
Effects of a Nutraceutical Multicompound, with Probiotics, Hericium, PEA, and Undaria in Patients with Irritable Bowel Syndrome.
Irritable bowel syndrome (IBS) is a functional gastrointestinal condition. Probiotics and other nutraceutical compounds can have specific indications in the context of IBS. A retrospective analysis was conducted on 123 IBS patients in order to evaluate the effects of an oral probiotic-based dietary supplement (Colicron, one cps/day for 4 wk) on stool consistency and pain intensity. Different time points were defined as follows: baseline (T0), 2 wk of treatment (T2), and 4 wk of treatment (T4). Stool consistency was assessed by using the Bristol Stool Scale. Pain intensity was evaluated by the Visual Analogue Scale (VAS). Patients who were initially categorized as normal retained regular bowel movements throughout the study. Both patients with constipation and diarrhea showed an improvement in the Bristol Stool Scale. The score increased from 1.5 ± 0.5 to 3.3 ± 0.7 (p < 0.001) and decreased from 6.5 ± 0.7 to 4.3 ± 0.9 (p < 0.001) at T4, respectively, compared to T0. The VAS score for pain in the pooled IBS patients improved from 6.7 ± 2.2 to 2.8 ± 1.9 at T0 vs T4 (p < 0.001), with a similar trend also observed when patients were categorized based on stool consistency: normal (from 5.2 ± 1.9 to 2.9 ± 1.7), constipation (from 7.5 ± 1.3 to 3.2 ± 2.2), and diarrhea (6.7 ± 2.3 to 2.5 ± 1.9) (p < 0.001).
Colicron could be useful in symptom relief, reducing abdominal pain and improving stool consistency of IBS patients. However, further controlled clinical trials are needed to confirm these preliminary findings.
期刊介绍:
The Journal of Dietary Supplements (formerly the Journal of Nutraceuticals, Functional & Medical Foods) has been retitled to reflect the bold departure from a traditional scientific journal presentation to a leading voice for anyone with a stake in dietary supplements. The journal addresses important issues that meet the broad range of interests from researchers, regulators, marketers, educators, and health professionals from academic, governmental, industry, healthcare, public health, and consumer education sectors. This vital tool not only presents scientific information but interprets it - helping you more readily pass it on to your students, patients, clients, or company.